Q&A: Late-Breaking REMIX-1 and REMIX-2 Data Demonstrated Efficacy of Remibrutinib in Chronic Spontaneous Urticaria
Allergist immunologist Giselle Mosnaim, MD, recently spoke with Dermatology Times to discuss late-breaking phase 3 REMIX-1 and REMIX-2 data presented at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.